Plus Therapeutics Announces Webinar to Present ReSPECT™ Glioblastoma Clinical Trial Update
Company Management and Principal Investigator of ReSPECT to Discuss Interim Data Webinar Scheduled for Thursday, November 19, 2020 at 4:30...
Month: November 2020
AIM ImmunoTech Provides Third Quarter 2020 Business Update
OCALA, Fla., Nov. 13, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM), an immuno-pharma company focused on the...
Fulcrum Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives...
Meridian Bioscience Reports Strong Fourth Quarter and Record Full-Year Fiscal 2020 Operating Results and Provides Fiscal 2021 Guidance
CINCINNATI, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the fourth quarter...
Progenity to Host Preeclampsia Virtual R&D Day on November 20, 2020
SAN DIEGO, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record...
Crinetics Hosting Key Opinion Leader Meeting Focusing on Oral Paltusotine for the Treatment of Acromegaly
Webinar Being Held on Friday, November 20th @ 11:00 am Eastern Time SAN DIEGO, Nov. 13, 2020 (GLOBE NEWSWIRE) --...
Entera Bio to Report Third Quarter 2020 Business and Financial Results on November 19, 2020
BOSTON JERUSALEM, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally...
Surface Oncology Announces SRF617 and SRF388 Will Advance to Combination and Expansion Stages of Ongoing Phase 1 Clinical Trials
Both programs have successfully escalated to dose levels demonstrating pharmacodynamic activity without dose-limiting toxicities Detailed clinical data for each program...
OncXerna Therapeutics to Participate at the Piper Sandler Virtual Healthcare Conference
WALTHAM, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-based biomarker...
BioCryst Presents Data Showing Sustained Attack Rate Reductions, Improved Patient Satisfaction and Quality of Life for HAE Patients Taking Berotralstat in APeX-2 Trial
—Data presented at 2020 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)— RESEARCH TRIANGLE PARK,...
BeyondSpring Subsidiary, Seed Therapeutics, Announces Research Collaboration and License Agreement with Lilly
- Seed Therapeutics to Use Proprietary “Molecular Glue” Protein Degradation Technology to Develop Potential New Medicines - NEW YORK, Nov....
Checkmate Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides an Update on Recent Progress
Presented new CMP-001 data in melanoma at SITC’s 35th Anniversary Annual Meeting CAMBRIDGE, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) --...
Bio-Path Holdings Reports Third Quarter 2020 Financial Results
Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc.,...
C4 Therapeutics to Present at the Jefferies Virtual London Healthcare Conference
WATERTOWN, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new...
BioXcel Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference
NEW HAVEN, Conn., Nov. 13, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage...
TG Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference
Fireside chat scheduled for Tuesday, November 17, 2020 at 2:20 PM ET/ 7:20 PM GMT NEW YORK, Nov. 13, 2020...
Sio Gene Therapies Announces Corporate Updates and Financial Results for Second Fiscal Quarter Ended September 30, 2020
Continued progress across pipeline of gene therapy programs, including recent IND clearance for AXO-AAV-GM2 in Tay-Sachs/Sandhoff diseases Completed rebranding to...
Prevail Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights
Patient Dosing Continues in the Phase 1/2 PROPEL Trial of PR001 for Parkinson’s Disease with GBA1 Mutations Phase 1/2 PROVIDE...
BioCryst Presents New Data Highlighting Burden of Therapy with Current Injectable Prophylaxis Medication for HAE
—Data presented at the 2020 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)— RESEARCH TRIANGLE...
Oyster Point Pharma Announces Clinical Data Presentations on OC-01 Nasal Spray for Dry Eye Disease at the American Academy of Ophthalmology 2020 Virtual Annual Meeting
Results from the Phase 2 IMPERIAL study illustrate OC-01 nasal spray caused a decrease in goblet cell size, as compared...